X0508 4 2025-11-25 0001581760 Life360, Inc. LIF 0001932498 Hulls Chris C/O LIFE360, INC. 1900 SOUTH NORFOLK STREET, SUITE 310 SAN MATEO CA 94403 true false Common Stock 2025-11-25 4 M 0 208987 2.15 A 685665 D Common Stock 2025-11-25 4 M 0 95833 13.35 A 781498 D Common Stock 2025-11-25 4 S 0 226556 76.91 D 554942 D Common Stock 2025-11-25 4 S 0 80193 77.56 D 474749 D Common Stock 2025-11-25 4 S 0 5000 78.38 D 469749 D Common Stock 2025-11-25 4 G 0 62500 0 D 407249 D Common Stock 2025-11-26 4 M 0 48164 8.19 A 455413 D Common Stock 2025-11-26 4 S 0 100465 78.62 D 354948 D Common Stock 2025-11-26 4 S 0 19535 79.11 D 335413 D Common Stock 195312 I Held by the Robin Hulls 2023 Irrevocable Trust Common Stock 195312 I Held by the Rose Hulls 2023 Irrevocable Trust Common Stock 195312 I Held by the Mckenzie Hulls 2023 Irrevocable Trust Common Stock 1846 I Held by ICCA Labs, LLC Stock Option (right to buy) 2.15 2025-11-25 4 M 0 208987 0 D 2027-10-24 Common Stock 208987 0 D Stock Option (right to buy) 13.35 2025-11-25 4 M 0 95833 0 D 2027-02-01 Common Stock 95833 4167 D Stock Option (right to buy) 8.19 2025-11-26 4 M 0 48164 0 D 2028-05-20 Common Stock 48164 233801 D Includes common stock and the number of shares of common stock underlying Chess Depositary Interests ("CDIs") as converted on a 1:3 common stock to CDI ratio. The CDIs are traded on the Australian Securities Exchange (the "ASX") and are held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Includes 137,853 restricted stock units previously granted, each of which represents a contingent right to receive one share of the Issuer's common stock upon vesting. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $76.25 to $77.245, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $77.25 to $78.21, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $78.32 to $78.43, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range. This transaction reflects a bona fide gift of the Issuer's stock to a donor-advised fund (DAF) for charitable purposes. The Reporting Person retains no beneficial ownership or control over the donated securities following the contribution. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $78.02 to $79.015, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $79.02 to $79.34, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range. Represents shares of the Issuer's common stock underlying 585,938 CDIs. The Reporting Person is a member of ICCA Labs, LLC, an entity that holds an aggregate of 8,219 shares of the Issuer's common stock. The number of shares held as reported herein by the Reporting Person represents his proportionate ownership interest in ICCA Labs, LLC. The stock option is fully vested and exercisable. The stock option vests and becomes exercisable as to 1/48th of the total number of shares in equal monthly installments beginning on February 1, 2022, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. The vesting terms for the stock option with an exercise price of $8.19 reported herein were inadvertently misreported on the Reporting Person's Form 3/A filed on July 20, 2022, and have been corrected as of this Form 4. /s/ Jay Sood, Attorney-in-Fact 2025-11-26